30 November 2017

PDMR Dealing

LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on November 29, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 10,000 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 106.85 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 135,787 Ordinary Shares, representing 0.13% of the Company’s issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.


1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	David Ebsworth
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Verona Pharma plc
b)	LEI	213800EVI6O6J3TIAL06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 5 pence each

	Identification code	GB00BYW2KH80

b)	Nature of the transaction	David Ebsworth purchased 10,000 Ordinary Shares
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		106.85 pence per Ordinary Share	10,000 Ordinary Shares

d)	Aggregated information	N/A

	- Aggregated volume

	- Price

e)	Date of the transaction	29 November 2017
f)	Place of the transaction	London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plc	Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer	info@veronapharma.com

Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)	Tel: +44 (0) 20 7710 7600 SNELVeronaPharma@stifel.com
Stewart Wallace / Jonathan Senior / Ben Maddison

Source: Verona Pharma plc

For further information please contact:

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

Stifel Nicolaus Europe Ltd (Nominated Adviser and UK Broker)
Jonathan Senior / Stewart Wallace
Tel: +44 (0)20 7710 7600

FTI Consulting
Simon Conway / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com

Download article Print article Email alerts

Verona Pharma plc

Site map